Giannakis, M., Le, D. T., Pishvaian, M. J., Weinberg, B. A., Papadopoulos, K. P., Shen, L., … An, M. M. (2023). Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321+pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Giannakis, Marios, Dung T. Le, Michael J. Pishvaian, Benjamin Adam Weinberg, Kyriakos P. Papadopoulos, Lin Shen, Jifang Gong, et al. “Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321+pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Giannakis M, Le DT, Pishvaian MJ, Weinberg BA, Papadopoulos KP, Shen L, et al. Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321+pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Giannakis, Marios, et al. “Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321+pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Giannakis M, Le DT, Pishvaian MJ, Weinberg BA, Papadopoulos KP, Shen L, Gong J, Li J, Strickler JH, Zhou A, Zhang W, Parikh AR, Deming DA, Falchook GS, Cai J, Rosenstein L, Dorr A, An MM. Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321+pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors. JOURNAL OF CLINICAL ONCOLOGY. 2023.